• Lalantha Leelarathna, Mark L Evans, Sankalpa Neupane, Gerry Rayman, Sarah Lumley, Iain Cranston, Parth Narendran, Katharine Barnard-Kelly, Christopher J Sutton, Rachel A Elliott, Vicky P Taxiarchi, Georgios Gkountouras, Matthew Burns, Womba Mubita, Naresh Kanumilli, Maisie Camm, Hood Thabit, Emma G Wilmot, and FLASH-UK Trial Study Group.
• From the Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre (L.L., W.M., N.K., M.C., H.T.), the Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and Health (L.L., H.T.), and the Centre for Biostatistics (C.J.S., V.P.T.), the Manchester Centre for Health Economics (R.A.E., G.G.), and the Manchester Clinical Trials Unit (C.J.S., M.B.), Division of Population Health, Health Service Research and Primary Care, University of Manchester, Manchester, Wellcome Trust-Medical Research Council Institute of Metabolic Science, National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge University Hospitals and University of Cambridge, Cambridge (M.L.E.), Elsie Bertram Diabetes Centre, Norfolk (S.N.), Norwich University Hospitals NHS Foundation Trust, Norwich (S.N.), the Diabetes and Endocrine Centre, Ipswich Hospital, East Suffolk and North Essex NHS Foundation Trust, Ipswich (G.R.), the Adam Practice, Upton and Poole, Dorset (S.L.), the Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Cosham, Portsmouth (I.C.), the Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, and University Hospitals Birmingham NHS Foundation Trust, Birmingham (P.N.), Barnard Health, Barnard Health Research Limited, Portsmouth (K.B.-K.), University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby (E.G.W.), and the University of Nottingham, Nottingham (E.G.W.) - all in the United Kingdom.
• N. Engl. J. Med. 2022 Oct 20; 387 (16): 1477-1487.

BackgroundIn persons with type 1 diabetes and high glycated hemoglobin levels, the benefits of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels are uncertain.MethodsIn a parallel-group, multicenter, randomized, controlled trial involving participants with type 1 diabetes and glycated hemoglobin levels between 7.5% and 11.0%, we investigated the efficacy of intermittently scanned continuous glucose monitoring as compared with participant monitoring of blood glucose levels with fingerstick testing. The primary outcome was the glycated hemoglobin level at 24 weeks, analyzed according to the intention-to-treat principle. Key secondary outcomes included sensor data, participant-reported outcome measures, and safety.ResultsA total of 156 participants were randomly assigned, in a 1:1 ratio, to undergo intermittently scanned continuous glucose monitoring (the intervention group, 78 participants) or to monitor their own blood glucose levels with fingerstick testing (the usual-care group, 78 participants). At baseline, the mean (±SD) age of the participants was 44±15 years, and the mean duration of diabetes was 21±13 years; 44% of the participants were women. The mean baseline glycated hemoglobin level was 8.7±0.9% in the intervention group and 8.5±0.8% in the usual-care group; these levels decreased to 7.9±0.8% and 8.3±0.9%, respectively, at 24 weeks (adjusted mean between-group difference, -0.5 percentage points; 95% confidence interval [CI], -0.7 to -0.3; P<0.001). The time per day that the glucose level was in the target range was 9.0 percentage points (95% CI, 4.7 to 13.3) higher or 130 minutes (95% CI, 68 to 192) longer in the intervention group than in the usual-care group, and the time spent in a hypoglycemic state (blood glucose level, <70 mg per deciliter [<3.9 mmol per liter]) was 3.0 percentage points (95% CI, 1.4 to 4.5) lower or 43 minutes (95% CI, 20 to 65) shorter in the intervention group. Two participants in the usual-care group had an episode of severe hypoglycemia, and 1 participant in the intervention group had a skin reaction to the sensor.ConclusionsAmong participants with type 1 diabetes and high glycated hemoglobin levels, the use of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels resulted in significantly lower glycated hemoglobin levels than levels monitored by fingerstick testing. (Funded by Diabetes UK and others; FLASH-UK ClinicalTrials.gov number, NCT03815006.).Copyright © 2022 Massachusetts Medical Society.

30 keywords...

hide…